

This document shows the changes that were made to EOD and Summary Stage 2018 for the SEER*RSA version 3.4 release.

[Table 1: Schema Redefine updates, Version 3.4](#)

[Table 2: Updated Schemas due to AJCC Version 9 rolling updates, Version 3.4](#)

[Table 3: Changes to EOD Schemas, Version 3.4](#)

[Table 4: Changes to Summary Stage, Version 3.4](#)

Table 1: Schema Redefine updates, Version 3.4

- Please see the Implementation Guidelines for a detailed listing of the conversion specifications for the impacted data items (EOD2018+, Summary Stage 2018+, SSDIs, and Grade).
- See also the SSDI Manual, Appendix D1 and D2 (new appendices) for a detailed listing of the primary site/histology combinations that were moved.
 - Conversion logic not included
- The Schema Redefine is managed by the SSDI WG. If you have questions, please post in the SSDI CAnswer Forum, general questions.

Table 2: Updated Schemas due to AJCC Version 9 rolling updates, Version 3.4

Schema	Applicable Years	Comments
Minor Salivary Gland	2027+	AJCC's Salivary Glands, Version 9, will be used with 2027+ diagnosis • NEW EOD Minor Salivary Gland 9: 2027+ (Schema ID: 09082) Summary Stage chapter (NEW): Minor Salivary Gland <i>Note: Prior to 2027, Minor Salivary Glands were collected based on the location of their primary site</i>
Colon and Rectosigmoid Junction	2027+	AJCC's Colon, Version 9, will be used with 2027+ diagnosis Note: For Version 9, the Colon and Rectum were divided into two protocols. The current Colon and Rectum schema (00200) has been split to match Version 9. No change in data, no registrar input needed There are now two EOD Colon and Rectosigmoid schemas • EOD Colon and Rectosigmoid Junction 8th: 2018-2026 (Schema ID: 00201) • EOD Colon and Rectosigmoid Junction Version 9: 2027+ (Schema ID: 09201) Summary Stage chapter: Colon and Rectum (2018+)
Rectum	2027+	AJCC's Rectum, Version 9, will be used with 2027+ diagnosis Note: For Version 9, the Colon and Rectum were divided into two protocols. The current Colon and Rectum schema (00200) has been split to match Version 9. No change in data, no registrar input needed There are now two EOD Rectum schemas • EOD Rectum 8th: 2018-2026 (Schema ID: 00202) • EOD Rectum Version 9: 2026+ (Schema ID: 09202) Summary Stage chapter: Colon and Rectum (2018+)

Schema	Applicable Years	Comments
Breast	2027+	AJCC's Breast, Version 9, will be used with 2027+ diagnosis There are now two EOD Breast schemas • EOD Breast 8th: 2018-2026 (Schema ID: 00480) • EOD Breast Version 9: 2027+ (Schema ID: 09480) Summary Stage chapter: Breast (2018+)
Conjunctiva	2027+	AJCC's Conjunctiva, Version 9, be used with 2027+ diagnosis There are now two EOD Conjunctiva schemas • EOD Conjunctiva 8th: 2018-2026 (Schema ID: 00650) • EOD Conjunctiva Version 9: 2027+ (Schema ID: 09650) Summary Stage chapter: Conjunctiva (2018+)
Melanoma Conjunctiva	2027+	AJCC's Conjunctiva Melanoma, Version 9, will be used with 2027+ diagnosis There are now two EOD Melanoma Conjunctiva schemas • EOD Melanoma Conjunctiva 8th: 2018-2026 (Schema ID: 00660) • EOD Melanoma Conjunctiva Version 9: 2027+ (Schema ID: 09660) Summary Stage chapter: Melanoma Conjunctiva (2018+)
Lacrimal Gland	2027+	AJCC's Lacrimal Gland, Version 9, will be used with 2027+ diagnosis There are now two EOD Lacrimal Gland schemas • EOD Lacrimal Gland 8th: 2018-2026 (Schema ID: 00690) • EOD Lacrimal Gland Version 9: 2027+ (Schema ID: 09690) Summary Stage chapter: Lacrimal Gland/Sac (2018+)

Note: Kidney Renal Pelvis renamed: Kidney Renal Pelvis and Ureter

Table 3: Changes to EOD Schemas, Version 3.4

Schema	Data Item	Code	Original Text	Updated/New Text
00161, 00169: Esophagus	EOD Regional Nodes	300	Supraclavicular (transverse cervical) lymph nodes	These nodes were moved to EOD Mets, Code 10
00270: Ampulla of Vater, 00302, 09302: NET Ampulla of Vater	EOD Regional Nodes	Notes	"Celiac nodes" listed under Regional Lymph Nodes	Celiac nodes moved to EOD Mets, code 10. Confirmed with AJCC that these are distant nodes.
09100: Oropharynx HPV-Associated, Version 9	EOD Regional Nodes	550	CLINICAL ASSESSMENT only Bilateral or contralateral lymph nodes, WITH clinical evidence of ENE	CLINICAL ASSESSMENT only Bilateral or contralateral lymph nodes, <6cm WITH clinical evidence of ENE <i>ERROR fixed</i>
09100: Oropharynx HPV-Associated, Version 9	EOD Regional Nodes	650	CLINICAL ASSESSMENT only Bilateral or contralateral lymph nodes > 6 cm WITH or WITHOUT clinical evidence of ENE	CLINICAL ASSESSMENT only Ipsilateral , bilateral or contralateral lymph nodes > 6 cm WITH or WITHOUT clinical evidence of ENE <i>ERROR fixed</i>
09360: Lung, v9	EOD Mets	20	Single distant lymph node involved Cervical Distant lymph nodes, NOS...	Single distant lymph node involved (see code 40 for multiple distant lymph nodes) Cervical Distant lymph nodes, NOS
00370, 09370: Pleural Mesothelioma	NA	NA	Primary sites included C340-C349	Primary site only C384
00480: Breast	EOD Primary Tumor	450, 700		These two codes were removed from EOD Primary Tumor Conversion being done for cases diagnosed 2018+ Code 450-converted to 400 Code 700-converted to 600

Schema	Data Item	Code	Original Text	Updated/New Text
00530: Corpus Carcinoma and Carcinosarcoma	EOD Primary Tumor	Note 2	Note 2: EID and SEIC Code 050 is for the following in situ histologies (behavior /2) only - Endometrial intraepithelial carcinoma (EID) (8380/2) - Serous endometrial intraepithelial carcinoma (SEIC) (8441/2)	Note 2: EIC and SEIC Code 050 is for the following in situ histologies (behavior /2) only - Endometrial intraepithelial carcinoma (EIC) (8441/2) - Serous endometrial intraepithelial carcinoma (SEIC) (8441/2)
00530: Corpus Carcinoma and Carcinosarcoma	EOD Primary Tumor	050	- Endometrial intraepithelial carcinoma (EIC) (8380/2) - Serous endometrial intraepithelial carcinoma (SEIC) (8441/2)	- Endometrial intraepithelial carcinoma (EIC) (8441/2) - Serous endometrial intraepithelial carcinoma (SEIC) (8441/2)
00650: Conjunctiva	EOD Primary Tumor	650	Brain Sinus Further contiguous extension Deriving RE for SS2018	Central nervous system Further contiguous extension Deriving D for SS2018 Note: Sinus moved to code 600 (RE)
00660: Melanoma Conjunctiva	EOD Primary Tumor	650	Sinus, NOS (Derives D for SS2018)	Moved to code 600 (Derives RE for SS2018)
00660: Melanoma Conjunctiva	EOD Primary Tumor	750	Central nervous system Further contiguous extension Deriving RE for SS2018	Central nervous system Further contiguous extension Deriving D for SS2018
00721, 09721: Brain	EOD Primary Tumor	Note	Note 4: Drop metastasis Discontiguous spread, or "drop metastasis" are coded in EOD mets.	Note 4: Tumor cells in CSF - Circulating cells in cerebral spinal fluid (CSF) WITHOUT other evidence of mets is coded to 700. - If there is CSF WITH other evidence of mets, see EOD mets code 70. Note 5: Drop metastasis - Discontiguous spread, or "drop metastasis" are coded in EOD mets.

Schema	Data Item	Code	Original Text	Updated/New Text
00721, 09721: Brain	EOD Mets	Note	Note 2: Leptomeningeal metastases - Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. - These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).	Note 2: Tumor cells in CSF - Circulating cells in cerebral spinal fluid (CSF) WITH other evidence of mets is coded to 70 - If there is CSF WITHOUT other evidence of mets, see EOD Primary Tumor code 700 Note 3: Leptomeningeal metastases - Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. - These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).
09724: Medulloblastoma	EOD Mets	Note 3	Note 3: Types of extension coded in this data item - The following adjacent structures/sites, by direct or contiguous extension, are coded to 25. - Adjacent connective/soft tissue - Adjacent muscle - Bone - Circulating cells in cerebral spinal fluid (CSF)	New Note 3: Note 3: Tumors in the CSF - The presence of circulating cells in the spinal fluid is coded to 15 WHEN there is no other extension (see codes 25-45) <i>Circulating cell in cerebral spinal fluid (CSF) was included in the wrong note.</i> Note 4: Types of extension coded in this data item - The following adjacent structures/sites, by direct or contiguous extension, are coded to 25. - Adjacent connective/soft tissue - Adjacent muscle - Bone - Major blood vessel(s)

Schema	Data Item	Code	Original Text	Updated/New Text
09724: Medulloblastoma	EOD Mets	Note 5 (Prev Note 4)	Note 5: Leptomeningeal metastases - Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. - These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 35).	Note 5: Leptomeningeal metastases - Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. - These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 35). - There are several ways that this spread can occur Code 15 when there are circulating cells in cerebral spinal fluid WITHOUT leptomeningeal metastasis or other contiguous involvement (see codes 25, 35, 45) Code 25 when there is Leptomeningeal metastasis WITHIN the Brain/CNS (intracranial spread) and WITHOUT spinal cord other or contiguous involvement (see codes 35 & 45) Code 35 when there is leptomeningeal metastasis WITHIN the spinal cord (extracranial spread) and WITHOUT other further contiguous involvement (see code 45) - This includes leptomeningeal metastasis or other extension in the Brain/CNS AND the spinal cord

Schema	Data Item	Code	Original Text	Updated/New Text
09724: Medulloblastoma	EOD Mets	25	Intracranial spread beyond a single lesion All sites	Intracranial spread beyond a single lesion Metastasis within CNS and CSF pathways: Brain and CNS only (intracranial) <i>Note: See code 35 for involvement of the spinal cord</i> • Carcinomatous meningitis • Drop metastasis • Leptomeningeal metastases • Meningeal carcinomatosis All sites
09724: Medulloblastoma	EOD Mets	35	Metastasis within CNS and CSF pathways • Carcinomatous meningitis • Drop metastasis • Leptomeningeal metastases • Meningeal carcinomatosis"	Metastasis within CNS and CSF pathways: Spinal cord (extracranial) <i>Note: Includes spinal cord AND Brain/CNS involvement. See code 25 for Brain/CNS involvement only</i> • Carcinomatous meningitis • Drop metastasis • Leptomeningeal metastases • Meningeal carcinomatosis"
00710: Lymphoma Ocular Adnexa	Main Page	Note		Note 4: Benign (/0) and Borderline (/1) Hematopoietic Tumors • For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. • For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753

Schema	Data Item	Code	Original Text	Updated/New Text
00790: Lymphoma	Main Page	Note		Note 5: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753
00795: Lymphoma CLL/SLL	Main Page	Note		Note 6: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753
00812: Primary Cutaneous Lymphomas	Main Page	Note		Note 3: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753

Schema	Data Item	Code	Original Text	Updated/New Text
00822: Plasma Cell Disorders	Main Page	Note		Note 3: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753
00830: HemeRetic	Main Page	Note		Note 6: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. See the individual EOD Data Items for further instructions Note: During the schema redefine, any /1 histologies associated with this schema were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753

Table 4: Changes to Summary Stage, Version 3.4

Summary Stage Chapter	Code	Original Text	Updated/New Text
HemeRetic	Note	Note: During the schema redefine, any /1 histologies associated with this chapter were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753	Note 7: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. - Code 9 for /0 and /1 Hematopoietic tumors
Lymphoma (including Lymphoma CLL/SLL)	Note	Note: During the schema redefine, any /1 histologies associated with this chapter were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753	Note 9: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. - Code 9 for /0 and /1 Hematopoietic tumors
Lymphoma Ocular Adnexa	7	Regional by Direct Extension Orbital adnexal lymphoma AND extraorbital lymphoma extending beyond the orbit to adjacent structures + Bone + Brain + Maxillofacial sinuses	Moved to code 7 (Distant) Note: There are only localized or distant tumors for Ocular Adnexal Lymphoma. Recommend that if you have any cases coded to 2 or 4 in this Summary Stage chapter, that you change it to 7. Assigning these structures to code 2 was an error

Summary Stage Chapter	Code	Original Text	Updated/New Text
Melanoma Conjunctiva	7	Sinus, NOS (code 2, Regional)	Sinus, NOS (code 7, Distant)
Plasma Cell Disorders	Note	Note: During the schema redefine, any /1 histologies associated with this chapter were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753	Note 3: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. Code 9 for /0 and /1 Hematopoietic tumors
Primary Cutaneous Lymphoma	Note	Note: During the schema redefine, any /1 histologies associated with this chapter were moved out of Brain, CNS Other, and Intracranial Gland schemas for primary sites C700-C729, C751-C753	Note 3: Benign (/0) and Borderline (/1) Hematopoietic Tumors - For the U.S /0 and /1 neoplasms are not reportable, except for primary sites C700-C729, C751-C753. - For Canada, refer to your specific province for reportability requirements. Code 9 for /0 and /1 Hematopoietic tumors